RxDoctor Payments Data

Andrew Olafsson, MD

Nephrology · Milwaukee, WINPI 1144279332

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $878 of the $994 with a category attached, or 88.4%. 11 manufacturers reported payments, led by AstraZeneca at 25.1% of the total. Reporting peaked in 2023 at $559 and has fallen 73.5% since, to $148 in 2025.

$994in general payments, 2019–2025

Across 24 payments — averaging $41.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • GSK$175
  • Amgen$125
  • Bayer$111
  • Otsuka America Pharmaceutical, Inc.$96
  • Sanofi-aventis U.S. LLC$88
  • plus $150 from 5 others

What the payments were for

  • Food & beverage$87888%
  • Education$11612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$994 in reported general payments places this provider in the 65th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$136,364
Medicare patients
272
Services billed
1,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate11$10,255
ProsolParenteral Amino Acid 20% No.150$8,284
Potassium Citrate ErPotassium Citrate33$5,350
Potassium Chloride50$4,965
Sevelamer Carbonate30$3,057
Calcium Acetate19$1,885
Doxazosin Mesylate79$1,011
Allopurinol74$903
Valsartan24$900
Hydralazine Hcl51$842
Losartan Potassium105$818
Calcitriol33$701
Furosemide83$598
Amlodipine Besylate74$400
Carvedilol40$381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$250$10,25511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 173 nephrology providers in Wisconsin.

Other nephrology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →